ArticleFrontiers in microbiology2015
Silver linings: a personal memoir about Hurricane Katrina and fungal volatiles.
Article in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Review
- In Vitro Systems for Toxicity Evaluation of Microbial Volatile Organic Compounds on Humans: Current Status and Trends.Journal of fungi (Basel, Switzerland) · 2022Review
- Relationship of environmental disturbances and the infectious potential of fungi.Microbiology (Reading, England) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the aftermath of Hurricane Katrina, the levees protecting New Orleans, Louisiana failed. Because approximately 80% of the city was under sea level, widespread flooding ensued. As a resident of New Orleans who had evacuated before the storm and a life-long researcher on filamentous fungi, I had known what to expect. After the hurricane I traveled home with a suitcase full of Petri dishes and sampling equipment so as to study the fungi that were "eating my house." Not only were surfaces covered with fungal growth, the air itself was full of concentrated mold odor, a smell that was orders of magnitude more funky than any damp, musty basement I had ever encountered. The smell made me feel bad and I had to take regular breaks as I sampled. Being a mycotoxin expert, I knew a fair amount about "sick building syndrome" but believed that it was difficult to get enough respiratory exposure to toxins to cause the array of symptoms associated with the syndrome. So why was I feeling sick? Some Scandinavian experts had hypothesized that mold volatile organic compounds (VOCs) might be the fungal metabolites to blame for sick building syndrome and the time in my smelly, mold infested home made me think they might be right. After securing a new job and establishing a new laboratory, I endeavored to test the hypothesis that some volatile mold metabolites might be toxic. My laboratory at Rutgers University has interrogated the role of VOCs in possible interkingdom toxicity by developing controlled microcosms for exposing simple genetic model organisms to the vapor phase of growing fungi. Both Arabidopsis thaliana and Drosophila melanogaster exhibit a range of toxic symptoms that vary with the species of fungus, the duration of exposure, and other experimental parameters. Moreover, low concentrations of chemical standards of individual fungal VOCs such as 1-octen-3-ol also exhibit varying toxicity and cause neurotoxicity in a Drosophila model. Collectively, these data suggest that fungal VOCs may contribute to some of the adverse health effects reported by people exposed to damp indoor environments and that biogenic gas phase molecules deserve increased attention by the research community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.